BiotechTube

NYESO-1c259 T cells

Phase 1/2Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer

Conditions

Ovarian Cancer

Trial Timeline

Jul 9, 2013 โ†’ Jun 6, 2017

NCT ID
NCT01567891

About NYESO-1c259 T cells

NYESO-1c259 T cells is a phase 1/2 stage product being developed by Adaptimmune Therapeutics for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01567891. Target conditions include Ovarian Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01567891Phase 1/2Completed

Competing Products

20 competing products in Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
33
pemetrexed + topotecanEli LillyPhase 1
33
arzoxifene hydrochlorideEli LillyPhase 2
52
LY4337713Eli LillyPhase 1
33
PrexasertibEli LillyPhase 2
52
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
44
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
52
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
52
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
41
Enzalutamide 40 MGAstellas PharmaPhase 2
52
ASP0739Astellas PharmaPhase 1/2
41
IMAB027Astellas PharmaPhase 1
33
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
52
Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection + Progesterone Soft CapsulesSun PharmaceuticalPhase 3
77

Other Products from Adaptimmune Therapeutics

Treatment with NY-ESO-1c259-modified T cellsPhase 1/2
33
GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + FludarabinePhase 1
25
WT-gag-TCR modified T cells + ฮฑ/6-gag-TCR modified T cellsPhase 1
25
Autologous Genetically modified T cells, MAGEA10แถœโทโนโถTPhase 1
25
GSK3901961 + Cyclophosphamide + FludarabinePhase 1
25